VHIO
Head and Neck & Gynecological Tumors Group
Josep Maria del Campo
Medical Oncologists and Clinical Fellows
Neus Basté, Irene Braña, Ana Oaknin, Víctor Rodríguez Freixinós
SUMMARY
Our group focuses on standard patient care as well as clinical research and as such, we are dedicated to developing novel anticancer drugs as well as participating in the revision of all Spanish guidelines in gynecological cancer. We are also members of some of the most relevant alliances in gynecology including the Gynecologic Cancer Inter Group (GCIG), European Network of Gynaecological Oncology Trial Groups (ENGOT), Grupo Español de Investigación en Cáncer de Ovario (Spanish Gynecologial Group – GEICO), and the Gynecologic Oncology Group (GOG).
In addition, we are involved in developing new strategies, approaches, and optimal trial design for research, and play a central role as members of multidisciplinary committees and teams in head, neck and gynecological cancer tumors. Our contribution, in close connectivity and collaboration with other professionals and specialties, leads to the establishment of new treatment protocols and clinical guidelines to further advance clinical practice. As a reference group for other specialties as well as several research centers of excellence, we have steadily increased the number of patients treated in clinical trials with new drugs. Currently we are involved in more than twenty trials as Principal Investigators and/or Coordinators of National and International investigational studies.
PUBLICATIONS
- Du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Bauman KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade Bittinger C, Wang Q, Crescenzo R, Harter P. Incorporation oz Pazopanib in maintenance theraphy of ovarian cancer. J Clin Oncol. 2014 Oct 20; 32(30):3374-82.
- Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul; 15(8):799-808.
- Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E, Cohen EE. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2014 Sep;25(9):1813-20.
- Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. J Clin Oncol. 2014 May 1;32(13):1302-8.
- Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20; 370(8):734-43.
MAIN RESEARCH PROJECTS
View- The genomic analysis of advanced Head and Neck Cancer Tumours, HPV positive or negative, in collaboration with various VHIO groups, including Molecular Oncology, and the Maxilo-Facial Surgery Department at the Vall d’Hebron University Hospital.
- Gene expression profile analysis associated with ovarian cancer dissemination comparing primary tumor, metastasis samples and ascitis. Collaboration with the Biomedicine and Translational Oncology Research Unit, Vall d’Hebron Research Institute, and the Pathology Department of the Vall d´Hebron University Hospital.
- Molecular profiling in gynecologic cancer and matched targeted therapy: a step towards personalized medicine. Analysis of patients treated in Phase I trials.
Molecular alterations and genetic changes in ovarian sex cord tumours and germ cell. Collaboration with Universitiy of Leuven (Belgium). - Oncogenic Mutations in Cervical Cancer. Implications on long-term outcomes (VHIO-ICO collaboration).